DRD2 and lung carcinoma: The D2R agonist stopped the growth of lung cancer in a human xenograft model, and some of the beneficial antiangiogenic effects of D2R DA-Ag may occur through the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (responsible for producing reactive oxygen species) since it promotes angiogenesis [86].